Lumos Pharma, Inc.
LUMO · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | -$0 | -$0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 34.7% | 562.2% | 36.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 96.8% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,783% | -2,100.5% | -13,534.8% | -15,308.9% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,659.4% | -2,039.5% | -13,230.4% | -3,370.8% |
| EPS Diluted | -4.18 | -3.71 | -3.65 | -0.84 |
| % Growth | -12.7% | -1.6% | -334.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |